948021-68-9Relevant articles and documents
Discovery of NR2B-selective antagonists via scaffold hopping and pharmacokinetic profile optimization
Anan, Kosuke,Masui, Moriyasu,Tazawa, Aya,Tomida, Minoru,Haga, Yoshihiro,Kume, Masaharu,Yamamoto, Shoichi,Shinohara, Shunji,Tsuji, Hiroki,Shimada, Shinji,Yagi, Shigenori,Hasebe, Nobuyoshi,Kai, Hiroyuki
supporting information, p. 1143 - 1147 (2019/03/05)
Selective N-methyl-D-aspartate receptor subunit 2B (NR2B) antagonists show potential as analgesic drugs, and do not cause side effects associated with non-selective N-methyl-D-aspartate (NMDA) antagonists. Using a scaffold-hopping approach, we previously identified isoxazole derivative 4 as a potent selective NR2B antagonist. In this study, further scaffold hopping of isoxazole derivative 4 and optimization of its pharmacokinetic profile led to the discovery of the orally bioavailable compound 6v. In a rat study of analgesia, 6v demonstrated analgesic effects against neuropathic pain.